ClinicalTrials.gg
CompletedNCT07097766HPVUpdated Nov 20, 2026

The Effect of Health Belief Model-Based Education and Motivational Interviewing on HPV (Human Papilloma Virus) Knowledge and Vaccine Awareness in Women

An interventional study of "HBM-Based Education and Motivational Interviewing" in Human Papillomavirus Infection, sponsored by Saglik Bilimleri Universitesi. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Health services research

How we know · 2 judgments

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Mar 2024, registered Jul 2025).
Updated Nov 20, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Papillomavirus Infections with a site in Turkey — 1 open to participants now, 2 under way, none of them phase 3. Papillomavirus Infections · Turkey.

Enrollment
14th of 15
60 · median 90
Started
2024
with 3 others
No phase
15 of 19
none open now
Registered
9th of 19
by date

Among the 19 studies in Papillomavirus Infections with a site in Turkey, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2024, is one of 15 with no phase, and was the 9th registered.

Papillomavirus Infections

581 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

1 of the 19 studies in Papillomavirus Infections with a site in Turkey is open now. Recruiting first, the newest first:

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Papillomavirus Infections with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to evaluate the effect of an educational intervention based on the Health Belief Model (HBM) combined with motivational interviewing on women's knowledge about Human Papillomavirus (HPV) infection and their awareness of HPV vaccination. The study will be conducted among women aged 18-45 who have not received the HPV vaccine. Participants in the intervention group will receive structured education and motivational interviews, while the control group will receive no intervention. Changes in HPV knowledge and vaccine awareness will be measured before and after the intervention using validated scales. The goal is to improve preventive behaviors and increase vaccine uptake through behavior-based education.

Read the detailed description

This randomized controlled trial is designed to assess the impact of education and motivational interviewing grounded in the Health Belief Model (HBM) on women's knowledge regarding HPV and awareness of the HPV vaccine. The study population consists of 18-45-year-old literate women who have not previously received HPV vaccination.

Participants will be randomly assigned to either an intervention group or a control group. The intervention group will receive a 3-session structured education program based on HBM constructs (perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action, and self-efficacy), supported by motivational interviewing techniques. The control group will receive no intervention.

Data collection will include pre- and post-intervention assessments using a validated HPV knowledge scale and vaccine awareness questionnaire. The expected outcome is a statistically significant improvement in knowledge and awareness in the intervention group.

This study aims to contribute to public health efforts in HPV prevention and vaccination promotion by utilizing a behavioral model in community education.

03

Conditions studied

  • Human Papillomavirus Infection

Keywords

  • HPV
  • Human Papillomavirus
  • HPV Vaccine
  • Health Belief Model
  • Motivational Interviewing
  • Vaccine Awareness
  • Women's Health
  • Cervical Cancer Prevention
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged between 18-45 years

Voluntary participation and providing

Not previously vaccinated against HPV

Ability to attend all three educational and motivational interview sessions

Literacy sufficient to complete study questionnaires

Exclusion criteria

Exclusion Criteria:

  • Women under 18 or over 45 years old

Prior HPV vaccination

Cognitive or psychiatric conditions that hinder participation

Currently participating in another HPV-related education or intervention study

Inability to attend all sessions of the intervention program

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Intervention Group

    Behavioral: "HBM-Based Education and Motivational Interviewing"

  • No intervention
    Control Group

    This group will not receive any educational intervention or motivational interviewing. Standard care or routine health information will be provided as per usual practice.

Interventions

  • Behavioral"HBM-Based Education and Motivational Interviewing"

    This intervention consists of a structured 3-session educational program and motivational interviews based on the Health Belief Model (HBM). It aims to increase knowledge about HPV infection and improve HPV vaccination awareness among women aged 18-45.

06

What researchers measure

Primary outcomes

  1. HPV Knowledge Score

    Participants' total score on an HPV knowledge questionnaire designed to assess understanding of HPV infection, transmission, and prevention.

    Time frame: 4 weeks after the intervention

Secondary outcomes

  1. HPV Vaccination Awareness Score

    Participants' awareness level regarding HPV vaccination, measured using a structured 10-item survey.

    Time frame: 4 weeks after the intervention

07

Study locations

1 site
  • Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi
    Üsküdar, Istanbul 34000, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — IPD and supporting documents will be available starting 6 months after the publication of the primary study results and will remain available for 5 years.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD and supporting documents will be available starting 6 months after the publication of the study results and will remain available for 5 years.

Access criteria: Qualified researchers may request access to the individual participant data by contacting the principal investigator. Access will be granted upon reasonable request and approval of a data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Sep 2024, 6 months.

Of 110 non-industry interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's 6 months is below that.

Counting every sponsor, half of 119 studies reached it within 26 months; a quarter within 10 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Aug 2025 → Mar 2024, primary completion Sep 2025 → Sep 2024 and completion Dec 2025 → Dec 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Jul 31, 2025
StartActual
Mar 1, 2024was Aug 2025
Primary completionActual
Sep 1, 2024was Sep 2025
CompletionActual
Dec 1, 2024was Dec 2025
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 20, 2026
Start date
Aug 1, 2025→Mar 1, 2024 (actual)
Nov 20, 2026
Primary completion
Sep 1, 2025→Sep 1, 2024 (actual)
Nov 20, 2026
Study completion
Dec 1, 2025→Dec 1, 2024 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Completed
    Start date Aug 1, 2025→Mar 1, 2024 (now actual)
    Primary completion Sep 1, 2025→Sep 1, 2024 (now actual)
    Study completion Dec 1, 2025→Dec 1, 2024 (now actual)
    + 3 other changes: verification date, responsible party and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07097766
Responsible party
Seda Ayyıldız (Principal Investigator, Saglik Bilimleri Universitesi) — Principal investigator
First posted
Jul 31, 2025
Start date
Mar 1, 2024
Primary completion
Sep 1, 2024
Completion
Dec 1, 2024
Last update
Nov 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion